Orexo AB (ST:ORX) — Market Cap & Net Worth
Market Cap & Net Worth: Orexo AB (ORX)
Orexo AB (ST:ORX) has a market capitalization of $48.39 Million (Skr449.63 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #22110 globally and #410 in its home market, demonstrating a -4.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orexo AB's stock price Skr12.80 by its total outstanding shares 35127056 (35.13 Million). Also see how large is Orexo AB's balance sheet for a full breakdown of the balance sheet.
Orexo AB Market Cap History: 2015 to 2026
Orexo AB's market capitalization history from 2015 to 2026. Data shows change from $237.21 Million to $48.39 Million (-12.88% CAGR). Also see Orexo AB cash conversion from operations for how efficiently the company converts equity into cash flow.
Orexo AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orexo AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ORX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.38x
Orexo AB's market cap is 4.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $142.14 Million | $705.80 Million | $29.00 Million | 0.20x | 4.90x |
| 2017 | $155.75 Million | $643.70 Million | $23.20 Million | 0.24x | 6.71x |
| 2018 | $222.28 Million | $783.10 Million | $137.90 Million | 0.28x | 1.61x |
| 2019 | $237.40 Million | $844.80 Million | $219.10 Million | 0.28x | 1.08x |
| 2020 | $189.01 Million | $663.60 Million | -$84.40 Million | 0.28x | N/A |
| 2021 | $130.42 Million | $565.00 Million | -$223.50 Million | 0.23x | N/A |
| 2022 | $71.30 Million | $624.30 Million | -$177.60 Million | 0.11x | N/A |
| 2023 | $58.44 Million | $638.80 Million | -$128.30 Million | 0.09x | N/A |
| 2024 | $66.15 Million | $590.00 Million | -$203.00 Million | 0.11x | N/A |
| 2025 | $113.78 Million | $26.00 Million | -$129.80 Million | 4.38x | N/A |
Competitor Companies of ORX by Market Capitalization
Companies near Orexo AB in the global market cap rankings as of September 19, 2026. Review Orexo AB (ORX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Orexo AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Orexo AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Orexo AB's market cap moved from $237.21 Million to $ 48.39 Million, with a yearly change of -12.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr48.39 Million | -57.48% |
| 2025 | Skr113.78 Million | +72.00% |
| 2024 | Skr66.15 Million | +13.20% |
| 2023 | Skr58.44 Million | -18.03% |
| 2022 | Skr71.30 Million | -45.33% |
| 2021 | Skr130.42 Million | -31.00% |
| 2020 | Skr189.01 Million | -20.38% |
| 2019 | Skr237.40 Million | +6.80% |
| 2018 | Skr222.28 Million | +42.72% |
| 2017 | Skr155.75 Million | +9.57% |
| 2016 | Skr142.14 Million | -40.08% |
| 2015 | Skr237.21 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Orexo AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.39 Million USD |
| MoneyControl | $48.39 Million USD |
| MarketWatch | $48.39 Million USD |
| marketcap.company | $48.39 Million USD |
| Reuters | $48.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more